FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1. | Name and Address of Company |
RepliCel Life Sciences Inc. (the “Company”)
Suite 2020 – 401 West Georgia Street
Vancouver, BC V6B 5A1
Item 2. | Date of Material Change |
June 25, 2015
Item 3. | News Release |
News Release was disseminated via CNW Group on June 26, 2015.
Item 4. | Summary of Material Change |
The Company announced that it completed its financing announced on June 1, 2015 to raise total gross proceeds of $2,038,278.83, which consisted of a brokered private placement of 4,834,471 units (each a “Unit”) at a price of $0.31 per Unit for gross proceeds of $1,498,686.01 and a non-brokered private placement of 1,740,622 Units at a price of $0.31 per Unit for gross proceeds of $539,592.82. Each Unit consists of one common share of the Company (each, a “Share”) and one Share purchase warrant, which will entitle the holder to purchase one additional Share for a period of three years from the closing of the private placement at a price of $0.51 per Share.
Item 5. | Full Description of Material Change |
5.1 | Full Description of Material Change |
See attached news release.
5.2 | Disclosure for Restructuring Transactions |
N/A
Item 6. | Reliance on subsection 7.1(2) or (3) of National Instrument 51-102 |
Not Applicable.
Item 7. | Omitted Information |
Not Applicable.
Item 8. | Executive Officer |
David Hall, President and Director 604.248.8730
Item 9. | Date of Report |
June 30, 2015